Timapiprant

Summary

Timapiprant (CHEMBL560993) is a phase-3 clinical-stage small molecule targeting PTGDR2; indicated across 4 conditions including asthma and allergic rhinitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (PTGDR2)
• Indications: 4 conditions
• Clinical trials: 11
• Chemistry: 348.4 Da · C21H17FN2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL560993
Name	Timapiprant
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11462174
Molecular formula	C21H17FN2O2
Molecular weight	348.4
InChIKey	FATGTHLOZSXOBC-UHFFFAOYSA-N

SMILES: CC1=C(C2=C(N1CC(=O)O)C=CC(=C2)F)CC3=NC4=CC=CC=C4C=C3

IUPAC name: 2-[5-fluoro-2-methyl-3-(quinolin-2-ylmethyl)indol-1-yl]acetic acid

Also known as: CHF-6532, OC-000459, Oc-459, Oc000459, OC000459, OC459, Odc-9101, Timapiprant, TIMAPIPRANT

Patent coverage: 114 distinct patent families (285 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 190 (67%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PTGDR2	DP2 receptor	Antagonist	7.89	0%	Q9Y5Y4

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prostacyclin receptor, Aldo-keto reductase family 1 member B1, Prostaglandin D2 receptor, Prostaglandin D2 receptor 2.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PTGDR2	8.22	IC50	6	nM	CHEMBL_ACT_2706461
PTGDR2	7.89	Ki	13	nM	CHEMBL_ACT_12163553
PTGDR2	7.72	IC50	19	nM	CHEMBL_ACT_12163542
PTGDR2	7.62	EC50	24	nM	CHEMBL_ACT_12163544
PTGDR2	7.55	IC50	28	nM	CHEMBL_ACT_12163543
PTGDR2	7.46	IC50	35	nM	CHEMBL_ACT_12163541
PTGDR2	7.36	IC50	44	nM	CHEMBL_ACT_2706473
PTGDR2	7	IC50	100	nM	CHEMBL_ACT_12163550
PTGDR2	6.89	IC50	130	nM	CHEMBL_ACT_13316912
P07943	6.26	IC50	550	nM	CHEMBL_ACT_12163545
PTGDR	5.14	IC50	7300	nM	CHEMBL_ACT_2706497

Target pathways

Aggregated over 1 target gene(s): PTGDR2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prostanoid ligand receptors	1	PTGDR2
G alpha (i) signalling events	1	PTGDR2

Dominant GO biological processes

GO term	Targets
chemotaxis	1
immune response	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
neuropeptide signaling pathway	1
calcium-mediated signaling	1
positive regulation of G protein-coupled receptor signaling pathway	1
cellular response to prostaglandin D stimulus	1
negative regulation of male germ cell proliferation	1
signal transduction	1

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
asthma	3	MONDO:0004979	MONDO:0004979
allergic rhinitis	2	MONDO:0011786	EFO:0005854
atopic eczema	2	MONDO:0004980	EFO:0000274
eosinophilic esophagitis	2	MONDO:0005361	EFO:0004232

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	8
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00290381	PHASE1/PHASE2	COMPLETED	The Effects of OC000459 on Nasal Mediators
NCT00697281	PHASE2	COMPLETED	OC000459 Dose Finding Study in Hay Fever Sufferers.
NCT01056692	PHASE2	COMPLETED	OC000459 Bronchial Allergen Challenge
NCT01056783	PHASE2	COMPLETED	Proof of Concept Study of OC000459 in Eosinophilic Esophagitis
NCT01057927	PHASE2	COMPLETED	Safety and Efficacy Study of OC000459 Dosed Twice Daily for 28 Days in Asthmatic Subjects
NCT01448902	PHASE2	COMPLETED	A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis
NCT02002208	PHASE2	COMPLETED	Effect of OC000459 on Moderate to Severe Atopic Dermatitis
NCT02560610	PHASE2	COMPLETED	Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
NCT02660489	PHASE2	COMPLETED	Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
NCT01056575	PHASE1	COMPLETED	Study to Evaluate the Potential for Interaction Between OC000459 and CYP 450 3A4
NCT02341521	PHASE1	COMPLETED	Evaluation of Metabolic Profile of OC000459

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

10 molecules share ≥1 primary target. Top 10 by shared-target count:

Molecule	Source	Status	Shared targets
INDOMETHACIN	ChEMBL + PubChem	Phase 4 (approved)	PTGDR2
LAROPIPRANT	ChEMBL	Phase 4 (approved)	PTGDR2
RAMATROBAN	ChEMBL	Phase 4 (approved)	PTGDR2
FEVIPIPRANT	ChEMBL	Phase 3	PTGDR2
SETIPIPRANT	ChEMBL	Phase 3	PTGDR2
AZD1981	ChEMBL	Phase 2	PTGDR2
BI-671800	ChEMBL	Phase 2	PTGDR2
FENTIAZAC	ChEMBL	Phase 2	PTGDR2
QAV680	ChEMBL	Phase 2	PTGDR2
VIDUPIPRANT	ChEMBL	Phase 2	PTGDR2